Reason #3: AML Is A Huge Market Opportunity
Should all continue to go well in trials, and onvansertib be approved by the FDA, the opportunity for Trovagene would be incredible.
Currently, it is estimated that by the year 2025, the AML market will grow to be worth about $2.2 billion annually. While it would be foolish to suggest that one new drug would take the lion’s share of this market, TROV doesn’t need that result.
Currently, TROV trades with a market cap of under $10 million. As such, if the company were to break into this market and access even 1% of the opportunity, it would represent a meaningful value addition for the company and its investors.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
Don’t Miss The Next Big Story!
Join our free mailing list below to receive real-time news alerts!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!